Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

NCT06190782 PHASE3 RECRUITING

Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1 inhibitor +/- chemotherapy alone. The primary end point was progression-free survival (PFS). The secondary end points included overall survival, side effects and local control.

Details

Lead sponsor	Fudan University
Phase	PHASE3
Status	RECRUITING
Enrolment	354
Start date	Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 27 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Esophageal Squamous Cell Carcinoma
• Oligometastatic Disease
• Radiotherapy

Interventions

• PD-1 inhibitor+/- chemotherapy combined with local therapy
• systemic therapy alone

Countries

China